Moti Vyas

Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.

Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and is currently undergoing evaluation through the FFLEX clinical study being run at major hospitals across Europe. FibroFix™ technology will then be rolled out to treat damaged cartilage in other joints while pipeline products beyond orthopaedics in which the application of great strength and tissue regeneration are key will also be developed. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.

Robust is building a new kind of Electric Vehicle company. Our vehicles and technology will be designed and engineered to challenge whats possible and to inspire people to explore the world in new ways. We have uniquely designed and developed proprietary EV drive control units, battery pack, Motor design and charger units - all in-house that will help us produce a “Made in India” EV motorcycle. In the past, we have built five different Electric vehicle prototypes in THREE different product segments. We have built three different motorcycles, including a performance motorcycle, one delivery vehicle catering to business and retail market, and one scooter for retail consumer market. All the prototypes are working prototypes that have been rigorously tested, driven and are in active use. Now, we are building another E-motorcycle to deliver unmatched customer value in the marketplace, and this is the motorcycle that will be commercialized.

Our Vision: We are building an asset-light modern retail network of tech-enabled mid-sized grocery stores under the brand “GULLYMART”. We partner with unbranded mid-sized stand-alone stores that wish to become part of a modern retail chain to improve their income and automate their end-to-end operations. We provide the store with an end-to-end tech-enabled solution consisting of exclusive supply, automatic and data-driven stock replenishment, increased sales, higher margin, superior fulfillment rates and access to credit. Our Story: Gully Network was founded by Ajay Nain and Prateek Chaturvedi, alumni of IIT Madras and IIM Ahmedabad. Both the founders had earlier worked in the FMCG & Pharma distribution space. They realized that stand-alone stores can never access the integrated retail-technology and higher margin of Modern Trade retail chains. Hence they took a comprehensive approach to solve their pain points in totality by making them part of a fully tech-enabled Modern retail chain. We are backed by Orios Venture Partners, Venture Catalysts, Inflection Point Ventures. We are also recognized by Flipkart under their first cohort. We have raised a total of $2M.

Oxford Endovascular is a spin out from Oxford University developing technology to prevent brain haemorrhage. OxiFlow™️ is a novel, next generation flow-diverter, laser-cut from nitinol that diverts blood flow away from intracranial aneurysms at risk of rupture. Competitors have adverse events related to poor placement of devices due to their inherent design weaknesses. OxiFlow™️ is a unique design that places more accurately and safely than existing products, reducing risk of complications and conforms to blood vessel shapes making more patients treatable. Patented in Europe, US, China & Japan. Created by world experts in the field, OxiFlow™ has gone through proof of concept pre-clinical studies that will be followed by a 1st in human study en-route to gaining FDA & CE mark.

Due Diligence AI that runs comprehensive financial, legal, regulatory and reputational risk analysis on any given target. We arm compliance and risk professionals with unrivaled automation and research capabilities helping them analyze targets in fraction of the time it would take otherwise. SignalX is used across industries by compliance, risk and legal professionals.

Driving Global AI Innovation with Advanced, Future-Ready Solutions. InfoBay.AI empowers enterprises and AI visionaries to design, refine, and scale the next generation of intelligent systems. By uniting cutting-edge research with real-world execution, we accelerate breakthroughs in AI reasoning, problem-solving, and complex programming capabilities. Our expertise spans robust data infrastructure, human-in-the-loop pipelines, and sophisticated post-training optimization—enabling AI labs and businesses worldwide to strengthen their models, enhance performance, and stay ahead in an increasingly competitive innovation landscape.

Kenyt.AIs product is a conversational customer and employee engagement platform, helping businesses to deeply engage with their customers through a high quality human-like experience. Kenyt Chatbots and Voicebots support multiple languages and produce superior engagement because of its advanced AI engine with 95% accuracy, which is way higher than the industry average. The system consists of multiple reusable workflows, like choosing an item on an ecommerce portal, processing payments, booking appointment, etc. and at the same time creating a permanent back-channel for marketing through messaging apps. As computing moves from touch/typing to chat & voice over next few years, Kenyt.AI with its deep conversational and workflow intelligence is best positioned to provide a high quality conversational experience to businesses globally, capitalizing on the market opportunity of upwards of $5B/annum. Founding team comes from IIT Roorkee and IIT Mumbai each having 15 years of relevant industry experience.

Gedea Biotech developes pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge, in the absence of itching. Standard treatment consists of antimicrobials, but recurrence rate is15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health in 2021 and research into novel non-antimicrobial based treatments is timely.

inHEART is committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease. We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.

Protinus Fashion Networking Private Limited is an information technology and services company based out of 365, 4th Main, 4th AvenueTeachers ColonyKoramangala, Bengaluru, India.

Building Instant Personal care brand

Sportido helps you find people and book places to play any sport. It connects you to other players nearby, as well as book courts, grounds, gyms, trainers etc. in your area. It is available as an app on iOS and Android. We are on a mission to increase participation in Sports and Fitness activities and our vision is to allow 10 million users across the globe​ by 2022. Download the app from - http://bit.ly/sportido_app Feel free to share your feedback on – info@sportido.com

Xplorabox was founded out of passion to create hands on activities for the kids which encourages them to explore, create and have fun in a constructive way. Our education and learning strategies have specially been designed to instill creative and constructive thoughts in kids, as well as enhance the sensitivity towards their environment. We have developed completely innovative way of learning, which are toys as box items. These toys create fun loving atmosphere for kids and give them a challenging environment to the extent where they can sensitize, develop their reasoning and relate with them in variety of ways. At Xplorabox, we have taken the step towards activity-based education through toys, which are reasonably priced, handy and exposition of creativity. The key purpose in producing these special toys is to sharpen the faculties of kids by spending quality time and to enhance learning in a purely non-competitive environment. Every child is important to us, and therefore, the boxes designed are very special. These boxes serve to fulfill the interest of child’s creativity and curiosity, while giving them a truly delightful retreat in their cozy living environments.

i2iFunding (RNVP Technology Pvt Ltd.) is a Reserve Bank of India (RBI) registered Non-Banking Financial Company - Peer to Peer Lending Platform (NBFC-P2P). i2i connects verified borrowers with retail lenders. i2i provides alternative investment option to Investors and affordable loans to Borrowers. Borrowers can use loans for gamut of reasons like purchase of consumer durable, debt consolidation (i.e. repayment of credit card debt etc.), medical expenses, education expenses, cash cycle optimization etc. Borrowers can get fast loans at attractive interest rates as we go beyond CIBIL and assess their profile based on 40+ parameters using our proprietary credit score model. On our platform, investors can directly lend money to real people and earn high returns on their investments in easy, secure and seamless manner. Apart from providing end to end loan services, i2i diligently uses unconventional data points of a borrower like education, employment, transactions, social network etc and not just solely dependent on CIBIL score for lending recommendations. This helps an Investor in greater understanding of borrowers riskiness which leads to better credit decisions. In the process, an investor gets an opportunity to earn higher risk adjusted returns​ while the borrower gets an opportunity to get funded at the lowest cost possible as per their risk profile and market based demand.

Cytovation is a clinical stage biotech developing CyPep-1, the first synthetic peptide engineered to selectively target tumor cell membranes based on their altered molecular composition. CyPep-1 lyses the cell membranes, exposes antigenic material from within the cancer cells, and induces a tumor-specific immune response. The described mode of action is effective across cancer types and highly synergistic with checkpoint inhibitors. CyPep-1 has entered clinical development in Q1 2019.

Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and is currently undergoing evaluation through the FFLEX clinical study being run at major hospitals across Europe. FibroFix™ technology will then be rolled out to treat damaged cartilage in other joints while pipeline products beyond orthopaedics in which the application of great strength and tissue regeneration are key will also be developed. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.

Robust is building a new kind of Electric Vehicle company. Our vehicles and technology will be designed and engineered to challenge whats possible and to inspire people to explore the world in new ways. We have uniquely designed and developed proprietary EV drive control units, battery pack, Motor design and charger units - all in-house that will help us produce a “Made in India” EV motorcycle. In the past, we have built five different Electric vehicle prototypes in THREE different product segments. We have built three different motorcycles, including a performance motorcycle, one delivery vehicle catering to business and retail market, and one scooter for retail consumer market. All the prototypes are working prototypes that have been rigorously tested, driven and are in active use. Now, we are building another E-motorcycle to deliver unmatched customer value in the marketplace, and this is the motorcycle that will be commercialized.

Our Vision: We are building an asset-light modern retail network of tech-enabled mid-sized grocery stores under the brand “GULLYMART”. We partner with unbranded mid-sized stand-alone stores that wish to become part of a modern retail chain to improve their income and automate their end-to-end operations. We provide the store with an end-to-end tech-enabled solution consisting of exclusive supply, automatic and data-driven stock replenishment, increased sales, higher margin, superior fulfillment rates and access to credit. Our Story: Gully Network was founded by Ajay Nain and Prateek Chaturvedi, alumni of IIT Madras and IIM Ahmedabad. Both the founders had earlier worked in the FMCG & Pharma distribution space. They realized that stand-alone stores can never access the integrated retail-technology and higher margin of Modern Trade retail chains. Hence they took a comprehensive approach to solve their pain points in totality by making them part of a fully tech-enabled Modern retail chain. We are backed by Orios Venture Partners, Venture Catalysts, Inflection Point Ventures. We are also recognized by Flipkart under their first cohort. We have raised a total of $2M.